Suppr超能文献

影响不同患者群体中万古霉素游离浓度的因素。

Factors impacting unbound vancomycin concentrations in different patient populations.

作者信息

Oyaert Matthijs, Spriet Isabel, Allegaert Karel, Smits Anne, Vanstraelen Kim, Peersman Nele, Wauters Joost, Verhaegen Jan, Vermeersch Pieter, Pauwels Steven

机构信息

University Hospitals Leuven, Department of Laboratory Medicine, Leuven, Belgium

KU Leuven-University of Leuven, Department of Clinical Pharmacology and Pharmacotherapy, Leuven, Belgium University Hospitals Leuven, Pharmacy Department, Leuven, Belgium.

出版信息

Antimicrob Agents Chemother. 2015 Nov;59(11):7073-9. doi: 10.1128/AAC.01185-15. Epub 2015 Sep 8.

Abstract

The unbound drug hypothesis states that only unbound drug concentrations are active and available for clearance, and highly variable results regarding unbound vancomycin fractions have been reported in the literature. We have determined the unbound vancomycin fractions in four different patient groups by a liquid chromatography tandem mass spectrometry (LC-MS/MS) method and identified factors that modulate vancomycin binding. We have further developed and validated a prediction model to estimate unbound vancomycin concentrations. Vancomycin (unbound and total) concentrations were measured in 90 patients in four different hospital wards (hematology [n = 33 samples], intensive care unit [ICU] [n = 51], orthopedics [n = 44], and pediatrics [age range, 6 months to 14 years; n = 18]) by a validated LC-MS/MS method. Multiple linear mixed model analysis was performed to identify patient variables that were predictive of unbound vancomycin fractions and concentrations. The variables included in the model were patient age, ward, number of coadministered drugs with high protein binding, kidney function (estimated glomerular filtration rate [determined by Chronic Kidney Disease Epidemiology Collaboration formula]), alpha-1-acid glycoprotein, albumin, total bilirubin, IgA, IgM, urea, and total vancomycin concentrations. In the pediatric cohort, the median unbound vancomycin fraction was 81.3% (range, 61.9 to 95.9%), which was significantly higher (P < 0.01) than the unbound fraction found in the three adult patient cohorts (hematology, 60.6% [48.7 to 90.6%]; ICU, 61.7% [47.0 to 87.6%]; orthopedics, 56.4% [45.9 to 78.0%]). The strongest significant predictor of the unbound vancomycin concentration was the total drug concentration, completed by albumin in the pediatric cohort and albumin and IgA in the adult cohorts. Validation of our model was performed with data from 13 adult patients. A mean difference of 0.3 mg/liter (95% confidence interval [CI], -1.3 to 0.7 mg/liter; R(2) = 0.99 [95% CI, 0.95 to 0.99]) between measured and calculated unbound vancomycin concentrations demonstrated that the predictive performance of our model was favorable. Unbound vancomycin fractions vary significantly between pediatric and adult patients. We developed a formula to estimate the unbound fraction derived from total vancomycin, albumin, and IgA concentrations in adult patients.

摘要

游离药物假说指出,只有游离药物浓度具有活性且可用于清除,并且文献中已报道了关于万古霉素游离分数的高度可变结果。我们通过液相色谱串联质谱(LC-MS/MS)方法测定了四个不同患者组中的万古霉素游离分数,并确定了调节万古霉素结合的因素。我们进一步开发并验证了一个预测模型来估计游离万古霉素浓度。采用经过验证的LC-MS/MS方法,对四个不同医院病房的90例患者(血液科[n = 33个样本]、重症监护病房[ICU][n = 51]、骨科[n = 44]和儿科[年龄范围,6个月至14岁;n = 18])的万古霉素(游离和总)浓度进行了测量。进行多元线性混合模型分析以确定可预测万古霉素游离分数和浓度的患者变量。模型中纳入的变量包括患者年龄、病房、同时使用的高蛋白结合药物数量、肾功能(估计肾小球滤过率[由慢性肾脏病流行病学协作公式确定])、α1酸性糖蛋白、白蛋白、总胆红素、IgA、IgM、尿素和总万古霉素浓度。在儿科队列中,万古霉素游离分数的中位数为81.3%(范围,61.9%至95.9%),显著高于三个成人患者队列中发现的游离分数(血液科,60.6%[48.7%至90.6%];ICU,61.7%[47.0%至87.6%];骨科,56.4%[45.9%至78.0%])(P < 0.01)。游离万古霉素浓度的最强显著预测因子是总药物浓度,在儿科队列中由白蛋白补充,在成人队列中由白蛋白和IgA补充。我们用13例成年患者的数据对模型进行了验证。测量的和计算的游离万古霉素浓度之间的平均差异为0.3 mg/L(95%置信区间[CI],-1.3至0.7 mg/L;R² = 0.99[95%CI,0.95至0.99]),表明我们模型的预测性能良好。儿科和成年患者之间的游离万古霉素分数差异显著。我们开发了一个公式来估计成年患者中由总万古霉素、白蛋白和IgA浓度得出的游离分数。

相似文献

1
Factors impacting unbound vancomycin concentrations in different patient populations.
Antimicrob Agents Chemother. 2015 Nov;59(11):7073-9. doi: 10.1128/AAC.01185-15. Epub 2015 Sep 8.
2
Factors impacting unbound vancomycin concentrations in neonates and young infants.
Eur J Clin Microbiol Infect Dis. 2018 Aug;37(8):1503-1510. doi: 10.1007/s10096-018-3277-8. Epub 2018 May 16.
4
Unbound fraction of vancomycin in intensive care unit patients.
J Clin Pharmacol. 2014 Mar;54(3):318-23. doi: 10.1002/jcph.175. Epub 2013 Sep 21.
6
Protein binding characteristics and pharmacokinetics of ceftriaxone in intensive care unit patients.
Br J Clin Pharmacol. 2015 Sep;80(3):525-33. doi: 10.1111/bcp.12636. Epub 2015 Jun 11.
8
9
Impact of hypoalbuminemia on voriconazole pharmacokinetics in critically ill adult patients.
Antimicrob Agents Chemother. 2014 Nov;58(11):6782-9. doi: 10.1128/AAC.03641-14. Epub 2014 Sep 2.

引用本文的文献

3
Factors affecting free vancomycin concentration and target attainment of free area under the concentration-time curve.
J Pharm Health Care Sci. 2025 Feb 18;11(1):13. doi: 10.1186/s40780-025-00419-4.
4
Mathematical Albumin Function for Neonates Undergoing Therapeutic Hypothermia in Comparison with Control Neonates.
J Clin Pharmacol. 2025 Jul;65(7):923-932. doi: 10.1002/jcph.70003. Epub 2025 Feb 11.
5
Vancomycin nephrotoxicity: A comprehensive clinico-pathological study.
PLoS One. 2024 Mar 7;19(3):e0295136. doi: 10.1371/journal.pone.0295136. eCollection 2024.
6
Severe Vancomycin Intoxication in an Infant Not Needing Dialysis: A Case Report and Literature Review.
Cureus. 2022 Nov 27;14(11):e31950. doi: 10.7759/cureus.31950. eCollection 2022 Nov.
7
Population pharmacokinetic model of vancomycin in postoperative neurosurgical patients.
Front Pharmacol. 2022 Sep 26;13:1005791. doi: 10.3389/fphar.2022.1005791. eCollection 2022.
8
Pharmacokinetics and pharmacodynamics of peptide antibiotics.
Adv Drug Deliv Rev. 2022 Apr;183:114171. doi: 10.1016/j.addr.2022.114171. Epub 2022 Feb 18.
10
Pharmacokinetics of Vancomycin in Critically Ill Children: A Systematic Review.
Eur J Drug Metab Pharmacokinet. 2022 Jan;47(1):31-48. doi: 10.1007/s13318-021-00730-z. Epub 2021 Nov 8.

本文引用的文献

1
Novel LC-MS/MS method for plasma vancomycin: comparison with immunoassays and clinical impact.
Clin Chim Acta. 2015 Feb 20;441:63-70. doi: 10.1016/j.cca.2014.12.012. Epub 2014 Dec 16.
2
Impact of hypoalbuminemia on voriconazole pharmacokinetics in critically ill adult patients.
Antimicrob Agents Chemother. 2014 Nov;58(11):6782-9. doi: 10.1128/AAC.03641-14. Epub 2014 Sep 2.
4
Unbound fraction of vancomycin in intensive care unit patients.
J Clin Pharmacol. 2014 Mar;54(3):318-23. doi: 10.1002/jcph.175. Epub 2013 Sep 21.
6
Quantification of vancomycin in human serum by LC-MS/MS.
Clin Chem Lab Med. 2013 Sep;51(9):1761-9. doi: 10.1515/cclm-2013-0142.
7
Implementation of a protocol for administration of vancomycin by continuous infusion: pharmacokinetic, pharmacodynamic and toxicological aspects.
Int J Antimicrob Agents. 2013 May;41(5):439-46. doi: 10.1016/j.ijantimicag.2013.01.009. Epub 2013 Mar 22.
9
Refining vancomycin protein binding estimates: identification of clinical factors that influence protein binding.
Antimicrob Agents Chemother. 2011 Sep;55(9):4277-82. doi: 10.1128/AAC.01674-10. Epub 2011 Jun 13.
10
Protein binding: do we ever learn?
Antimicrob Agents Chemother. 2011 Jul;55(7):3067-74. doi: 10.1128/AAC.01433-10. Epub 2011 May 2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验